At the core of this gathering was the SCAI’s mission to foster scientific innovation, policy advancement, and professional growth within cardiovascular intervention. With cardiovascular disease claiming close to one million lives annually across North America alone—surpassing fatalities caused by respiratory diseases and cancers combined—the urgency to deepen understanding and refine intervention techniques in this arena cannot be overstated. The multidisciplinary sessions spanned coronary artery disease, structural heart disease, peripheral artery disease, pharmacotherapy, and even considerations emerging from the COVID-19 pandemic’s cardiovascular impacts.

A prominent focus lay on coronary heart disease, the most prevalent form of cardiovascular illness worldwide. Experts presented new clinical trials and evidence aimed at refining the acute management of myocardial infarctions and cardiogenic shock. Notably, the SELUTION DeNovo Trial unveiled data on Sirolimus Eluting Balloons for acute coronary syndrome patients, potentially redefining percutaneous intervention methods with drug-eluting balloon technologies targeted at reducing restenosis and revascularization rates. Additional presentations delved into strategies for reducing mortality in cardiogenic shock and identifying clinically important subgroups post-STEMI utilizing data from large-scale registries and randomized trials.

Structural heart disease, affecting millions globally, formed another critical topic area. The Scientific Sessions highlighted technological advancements such as transcatheter mitral valve replacement with devices like the AltaValve—a transcatheter prosthetic featuring atrial fixation designed to improve procedural feasibility and one-year patient outcomes in mitral valve interventions. These innovations could revolutionize therapy by making structural interventions less invasive, reducing surgical risks, and expanding treatment candidacy among high-risk patients previously limited by anatomy or comorbidity burdens.

Pharmacotherapy research underscored its integral role in cardiovascular treatment regimens. Presenters discussed the unaddressed residual risk in lipid management elucidated by elevated Lipoprotein(a) levels, based on rigorous analysis from NIH randomized trials. Such insights drive the refinement of lipid-lowering protocols beyond conventional LDL cholesterol targets. Additional data on the impact of SGLT2 inhibitors post-percutaneous coronary intervention (PCI) in patients exhibiting type 2 diabetes mellitus and coronary artery disease provided compelling evidence for integrating these agents into comprehensive secondary prevention strategies.

Peripheral artery disease (PAD) emerged as a critical area given its prevalence—affecting an estimated 10 million adults over 40 in the United States alone—and its status as the leading cause of limb amputation worldwide. The conference showcased novel interventional approaches like transcatheter arterialization of deep veins for chronic limb-threatening ischemia (CLTI), as demonstrated in the PROMISE III study, which assessed quality of life and clinical outcomes at six months post-procedure. Comparisons between radial-to-peripheral versus traditional femoral access for PAD revascularization in the CARPOOL study further revealed procedural nuances impacting patient recovery and complication rates.

The lingering cardiovascular ramifications of the COVID-19 pandemic were addressed with emerging registry data providing longitudinal insights into one-year outcomes for patients experiencing ST-segment elevation myocardial infarction (STEMI) concurrent with COVID-19 infection. Such studies contribute to clarifying whether the pandemic catalyzed increased myocardial infarction rates through viral pathology or indirect effects, shaping future post-discharge risk stratification and secondary prevention algorithms.

Beyond clinical trials and device trials, the summit fostered vital cross-border collaboration, emphasizing the integration of multidisciplinary professional knowledge to elevate care standards globally. Leaders from both SCAI and CAIC-ACCI accentuated the importance of combining rigorous education, comprehensive research, and shared innovation to empower cardiology professionals in making evidence-based, patient-centered decisions, ultimately translating into improved clinical outcomes.

This edition of the Scientific Sessions solidified SCAI’s role at the vanguard of interventional cardiology advancement, delivering an expansive program rich with live case demonstrations, featured clinical research, and novel guideline presentations. The seamless cooperation between American and Canadian interventional communities exemplifies international synergy, strengthening the collective capacity to tackle cardiovascular health’s evolving challenges.

For participants at all career stages—from fellows to seasoned experts—the conference provided unparalleled opportunities for professional development through leadership sessions, networking, and exposure to translational science bridging bench discovery with bedside application. As the prevalence of cardiovascular diseases continues to impose profound individual and societal burdens, the acceleration of innovation and knowledge dissemination remains imperative.

In sum, the SCAI Scientific Sessions 2026 & CAIC-ACCI Summit represented more than an academic convention; it symbolized the unrelenting pursuit of excellence in cardiovascular intervention. By elucidating novel therapeutics, optimizing procedural strategies, and exploring emerging disease intersections such as COVID-19, the summit accentuated the dynamic evolution within interventional cardiology poised to improve patient lives worldwide.

Subject of Research: Interventional cardiology advancements, clinical outcomes in coronary and structural heart diseases, peripheral artery disease treatment, pharmacotherapy in cardiovascular disease, and cardiovascular impacts of COVID-19.

Article Title: Breakthroughs and Innovations in Interventional Cardiology Spotlighted at SCAI Scientific Sessions 2026 & CAIC-ACCI Summit

News Publication Date: April 8, 2026

Web References:

• https://www.scai.org/education-and-events/events-schedule/scai-2026-scientific-sessions-caic-acci-summit
• https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html
• https://caic-acci.org/

Image Credits: Society for Cardiovascular Angiography & Interventions and Canadian Association of Interventional Cardiology

Keywords: Interventional Cardiovascular Medicine, Coronary Heart Disease, Structural Heart Disease, Peripheral Artery Disease, Pharmacotherapy, COVID-19 Cardiovascular Impact, Transcatheter Mitral Valve Replacement, Sirolimus Eluting Balloons, SGLT2 Inhibitors, Cardiogenic Shock, Late-Breaking Clinical Trials, Cardiovascular Innovation

ST-segment elevation myocardial infarction, or STEMI, represents the gravest form of heart attack characterized by a complete blockage of a major coronary artery. This blockage halts blood flow to vital regions of the heart muscle, often resulting in extensive myocardial damage. The urgency in STEMI management stems from the maxim “time is muscle,” emphasizing that every minute without reperfusion compounds myocardial injury. The standard-of-care response involves rapid PCI, where interventional cardiologists deploy stents to reopen occluded arteries, thereby restoring blood flow and preserving heart function. However, while PCI is lifesaving, it often fails to prevent substantial myocardial necrosis, and many patients suffer adverse outcomes, including heart failure or death.

For decades, the scientific community has explored adjunctive therapies that might reduce infarct size by supporting the heart before and during PCI. Among these is the concept of “left ventricular unloading” using percutaneous microaxial pumps like the Impella CP. This device mechanically ejects blood from the left ventricle into the aorta, theoretically reducing ventricular workload, decreasing myocardial oxygen consumption, and thereby limiting ischemic injury. Experimental models have suggested that initiating unloading approximately 30 minutes before PCI could enhance myocardial salvage by allowing the heart to rest and potentially improve microvascular perfusion.

The STEMI-Door to Unload (DTU) trial was designed as the first large-scale, randomized controlled investigation to evaluate whether intentional delay in PCI combined with mechanical unloading could reduce infarct size in patients with anterior STEMI who are not in cardiogenic shock. The trial recruited 527 patients presenting within five hours of symptom onset at 55 emergency departments across five countries. Participants were randomized to receive either early mechanical unloading with the Impella CP device followed by delayed PCI or immediate PCI without mechanical support. The primary endpoint focused on infarct size measured by cardiac magnetic resonance imaging (MRI) performed three to five days post-intervention.

Intriguingly, the study found that while the Impella group demonstrated a modest reduction in infarct size—30.8% of left ventricular mass compared to 31.9% in the control group—this difference failed to achieve statistical significance. More importantly, this lack of significant infarct reduction came despite a nearly 47-minute increase in ischemic time due to the procedural delay from pump insertion. This suggests that left ventricular unloading may confer protective myocardial effects that counterbalance the harm of delayed reperfusion, a finding that warrants further exploration into potential mechanisms.

Safety outcomes revealed a notable trade-off; patients receiving the Impella device experienced a higher incidence of bleeding and vascular complications, at a rate exceeding the prespecified safety performance goal. These adverse events were primarily attributed to the invasive nature of the insertion procedure and the necessary anticoagulation protocols. While cardiovascular mortality rates did not differ significantly between the groups, these safety concerns highlight the complexity of balancing interventional benefits with procedure-related risks.

Dr. Stone emphasized that despite the absence of primary endpoint success, the DTU trial offers critical insights into myocardial protection strategies during STEMI treatment, particularly the nuanced interplay between ischemic time and mechanical circulatory support. The finding that infarct size was not exacerbated by reperfusion delay challenges assumptions about time-dependent myocardial injury and suggests a contributory role of unloading in myocardial recovery. Additionally, adjunctive pharmacologic agents such as nitroglycerin or beta blockers administered during unloading may optimize hemodynamics and enhance pump efficiency, indicating a fertile avenue for future combinatory therapies.

This study’s implications extend beyond the negative result of infarct reduction, urging a re-examination of device-based strategies in non-shock STEMI patients and encouraging exploration of synergistic interventions. Given the considerable morbidity associated with large myocardial infarctions and the persistent challenges in reducing infarct size, the DTU trial underscores the imperative for innovative, evidence-based approaches that integrate mechanical and pharmacologic modalities in acute cardiac care.

The trial also sheds light on the critical need for patient selection and procedural optimization when utilizing mechanical circulatory support devices. While the Impella CP saves lives in cardiogenic shock, its routine use in non-shock STEMI patients is not currently advisable without further evidence. However, the concept of left ventricular unloading remains promising, particularly if future studies can delineate protocols that minimize complications and maximize myocardial salvage, perhaps through novel device technologies or refined timing strategies.

Mount Sinai Health System’s Fuster Heart Hospital, renowned for its cardiology and cardiac surgery programs, spearheaded this landmark research. Their commitment to advancing cardiovascular medicine is reflected in their ranking as No. 2 nationally and No. 1 in New York according to U.S. News & World Report, as well as their reputation as a global leader in specialized cardiac care. This trial exemplifies Mount Sinai’s role at the forefront of translational research dedicated to improving patient outcomes in cardiovascular disease.

In conclusion, the STEMI-Door to Unload (DTU) randomized trial represents a critical juncture in cardiac intervention research. The failure to demonstrate significant infarct size reduction with mechanical unloading prior to PCI in anterior STEMI without shock challenges existing paradigms and directs attention toward more nuanced therapeutic strategies. Future investigations may uncover combinations of unloading with pharmacological or other evolving therapies that more effectively preserve myocardial tissue and enhance survival and quality of life for high-risk heart attack patients.

Subject of Research: People
Article Title: Left Ventricular Unloading in Anterior STEMI without Shock: The STEMI Door to Unload (DTU) Randomized Trial
News Publication Date: 28-Mar-2026
Web References: Not provided
References: Published in the Journal of the American College of Cardiology
Image Credits: Not provided
Keywords: Heart attack, STEMI, myocardial infarction, left ventricular unloading, Impella CP, percutaneous coronary intervention, microaxial flow pump, infarct size, cardiogenic shock, myocardial protection, clinical trial, cardiac MRI

Historically, cardiologists have grappled with the question of whether to limit stenting procedures to the culprit artery—the artery directly causing the infarction—or to pursue complete revascularization by stenting all obstructive coronary lesions identified during the acute event. Prior randomized controlled trials hinted that comprehensive treatment decreased non-fatal cardiac events, yet the impact on vital outcomes such as death from cardiovascular causes remained inconclusive. This latest large-scale meta-analysis aggregates data across multiple international cohorts to provide the statistical power needed to clarify these critical clinical uncertainties.

The study synthesized data from six major randomized clinical trials, encompassing a cohort of 8,836 patients presenting with myocardial infarction. Participants had a median age of 65.8 years and included a diverse demographic of over two thousand women and more than six thousand men. The extensive follow-up period of three years allowed robust assessment of both short-term and longer-term cardiovascular outcomes, ensuring that observed effects were durable and clinically relevant.

Patients randomized to complete revascularization—characterized by deploying stents not only in the infarct-related artery but also targeting significant obstructive lesions in bystander arteries—demonstrated a pronounced survival benefit. Specifically, the incidence of cardiovascular death or subsequent myocardial infarction was lowered by 25%, with absolute event rates falling to 9.0% from 11.5% when compared with culprit-only interventions. This indicates a noteworthy relative risk reduction, underlining the strong protective effect of this comprehensive interventional strategy.

Further critical details emerged regarding specific endpoints: cardiovascular mortality diminished from 4.6% in the culprit-only group to 3.6% in those receiving full revascularization, translating to a 24% relative decrease. Additionally, all-cause mortality was reduced by 15%, a finding of immense importance given the diverse etiologies of death in this population. Importantly, non-cardiovascular mortality rates, including deaths related to malignancies or infections, did not differ significantly between the groups, reinforcing that the observed benefits are specifically cardiovascular in nature.

The reduction in recurrent myocardial infarctions among patients undergoing complete revascularization signifies not only an improvement in survival but also a meaningful enhancement of quality of life. Recurrent infarctions carry significant morbidity, often precipitating progressive cardiac dysfunction, heart failure, and diminished exercise capacity. By curbing these events, comprehensive stenting strategies contribute to improved clinical outcomes and reduced healthcare burden.

An intriguing facet of this analysis is the consistency of benefits across the spectrum of myocardial infarction presentations. Both STEMI (ST-segment elevation myocardial infarction), which involves sudden, complete occlusion of a coronary artery, and NSTEMI (non-ST-segment elevation myocardial infarction), typically characterized by partial artery blockage causing subtler ischemia, exhibited similar advantages when complete revascularization was undertaken. This broad applicability enhances the generalizability and clinical adoption of the approach.

Equally notable is the finding that these benefits transcended age groups, confidently extending to both younger and elderly patients. This has meaningful implications for clinical decision-making, as older patients often present with complex coronary artery disease and comorbidities that influence therapeutic strategies. The data support a more aggressive interventional approach irrespective of age once the patient is deemed suitable for percutaneous coronary intervention.

The study’s robust design incorporated modern standard-of-care medical therapies, including dual antiplatelet regimens, statins, ACE inhibitors or angiotensin receptor blockers, and beta-blockers. This congruence with contemporary pharmacotherapeutic practices ensures that the survival benefits observed are additive to optimal medical treatment rather than an artifact of outdated protocols. Thus, the incremental advantage offered by complete revascularization is a testament to the power of combining pharmacology and mechanical intervention.

Insights from Dr. Shamir R. Mehta, senior interventional cardiologist at McMaster University and principal investigator on the study, highlight the clinical importance of these findings. Dr. Mehta emphasizes that complete revascularization is one of the few life-saving procedures currently available that simultaneously prevents future heart attacks while prolonging life itself. This endorsement from a leading expert underscores the potential for widespread paradigm shifts in interventional cardiology practice to maximize patient survival.

This research, published in the prestigious journal The Lancet and unveiled during the 2025 American Heart Association Scientific Sessions, carries profound implications for clinical guidelines and practice. The evidence is poised to influence recommendations globally, prompting cardiologists to reconsider strategies for managing multivessel coronary artery disease in the acute myocardial infarction setting.

In conclusion, this landmark international analysis unequivocally establishes that in patients presenting with myocardial infarction and multivessel coronary artery disease, complete revascularization via stenting substantially lowers cardiovascular mortality, reduces recurrent myocardial infarction, and enhances overall survival beyond culprit-artery only intervention. The integration of contemporary guideline-directed medical therapy further amplifies these life-saving benefits, positioning complete revascularization as a cornerstone therapeutic approach in modern interventional cardiology.

Subject of Research: Cardiovascular interventions in acute myocardial infarction—complete versus culprit-only artery revascularization.

Article Title: Complete revascularization in myocardial infarction significantly reduces cardiovascular mortality and recurrent heart attacks.

News Publication Date: 9-Nov-2025

Web References:
10.1016/S0140-6736(25)02170-1

Keywords: Cardiovascular disorders, myocardial infarction, complete revascularization, percutaneous coronary intervention, stenting, cardiovascular mortality, STEMI, NSTEMI, clinical trials, interventional cardiology, coronary artery disease.

Annapoorna Kini, MD, acclaimed for her leadership at the Cardiac Catheterization Lab, will helm the new AI Research Lab. Dr. Kini and her team are celebrated for their exceptional safety records and outstanding patient outcomes in treating intricate cardiology cases. The initiative aims to sculpt a future where AI serves as a crucial tool, enabling healthcare professionals to focus their efforts on areas with the greatest need, thereby optimizing resource allocation and improving overall patient care.

While many are skeptical about AI’s potential, Dr. Kini asserts that the technology can substantially improve traditional techniques, unlocking previously unattainable approaches. In the future, she envisions numerous workflows being enhanced by AI, refining how healthcare providers interact with and treat their patients. This preemptive integration of AI in cardiology signifies a foundational shift towards utilizing technology to address healthcare challenges proactively.

Historically, Mount Sinai’s Cath Lab has been at the forefront of adopting emerging AI technologies. The lab has already begun implementing AI applications to augment patient engagement and improve care coordination. The establishment of the AI Research Lab marks the next evolutionary phase, where the integration of advanced AI technologies into both research and clinical practices is set to transform patient experiences and outcomes.

The Research Lab is not merely an academic endeavor; it emphasizes practical applications that will directly impact interventional cardiology. From analyzing existing data to optimizing treatment protocols, the lab’s work aims to leverage AI’s capabilities to foster groundbreaking insights. The focus will encompass everything from procedural advancements to educational initiatives, ultimately shaping how healthcare providers approach patient care and management.

To commemorate the launch of the lab, Dr. Kini and her team are organizing the lab’s inaugural AI Symposium. Scheduled for September 15, the symposium will bring together thought leaders in cardiology and AI, fostering discussions that underscore the significance of this new endeavor. The event is poised to serve as a platform for sharing knowledge, promoting collaboration, and driving innovation in cardiology through AI.

The dedication of the Samuel Fineman Cardiac Catheterization Artificial Intelligence Research Lab is a profound tribute to Samuel Fineman, whose legacy continues to resonate within the walls of Mount Sinai. Following his passing in 2021 and the generous endowment he left, the lab was specifically established in his memory. This act of generosity not only honors his contributions but also ensures the continuity of exceptional cardiac care for future generations of patients.

As the lab moves forward, Dr. Kini’s leadership will be pivotal in steering AI research efforts. This includes exploring groundbreaking concepts in interventional cardiology that could redefine clinical standards and patient care. The collaborative nature of the lab will be instrumental in uncovering insights that enhance healthcare delivery, particularly in the realms of risk assessment and treatment planning.

Additionally, Dr. Samin K. Sharma, another leading figure in the realm of cardiovascular care, expressed his pride in the progressive mindset of the Mount Sinai team. His confidence in leveraging AI technologies exemplifies a collective commitment among hospital leaders to maintain high standards of care. The collaboration between pioneer cardiologists and data-driven solutions is set to elevate the quality of cardiac care delivered at Mount Sinai to unprecedented heights.

Mount Sinai Fuster Heart Hospital’s reputation as a leading institution in cardiology and heart surgery is well-established; it ranks as the second-best nationally and holds the top position in New York. This neural lab venture further cements Mount Sinai’s commitment to excellence and innovation, showcasing a dedication to providing the highest quality of care for its patients. The blend of clinical expertise with technological innovation encapsulates the hospital’s ethos, reflecting its status as a global leader in healthcare.

In conclusion, the establishment of The Samuel Fineman Cardiac Catheterization Artificial Intelligence Research Lab at Mount Sinai represents a monumental leap toward the future of interventional cardiology. This initiative encompasses a profound dedication to improving patient outcomes through the strategic use of AI, with Dr. Kini at the helm guiding the efforts of a talented team of experts. The lab not only prioritizes patient care but honors a legacy while looking forward to a future rife with possibility, innovation, and enhanced healthcare delivery.

The journey of integrating artificial intelligence into cardiology will undoubtedly generate waves of change, and as the team at Mount Sinai continues to pioneer these advancements, the implications for patient care are vast and transformative. The world watches as Mount Sinai sets a benchmark for the intersection of AI and medicine, priming the stage for a new era in cardiac care that promises to enhance lives and redefine healthcare dynamics.

Subject of Research: Artificial Intelligence in Interventional Cardiology
Article Title: Mount Sinai Launches The Samuel Fineman Cardiac Catheterization Artificial Intelligence Research Lab
News Publication Date: September 1, 2023
Web References: Mount Sinai Health System
References: U.S. News & World Report
Image Credits: Credit: Mount Sinai Health System

Keywords

Dr. Mehran, serving as Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai, has been a pivotal figure in the global cardiology community. Her work primarily focuses on devising novel randomized clinical trials and outcome research frameworks that ensure high standards of evidence-based practice. Her scientific influence extends through her prolific authorship of over 2,000 peer-reviewed articles, influencing clinical guidelines and therapeutic strategies for acute and chronic cardiovascular conditions.

One of the technical hallmarks of Dr. Mehran’s research resides in personalized cardiovascular medicine. She has been instrumental in developing validated individual risk scores that predict the probability of procedural complications such as bleeding and acute kidney injury. These risk stratification tools represent a vital advancement for tailoring therapeutic interventions to individual patient risk profiles, thereby improving procedural safety and optimizing overall clinical outcomes.

Her research methodology uniquely integrates large-scale, multicenter randomized trials with sophisticated outcome analytics, advancing the understanding of interventional procedures such as percutaneous coronary intervention (PCI). By meticulously examining factors that influence procedural success and patient recovery, her work enables clinicians to refine pre-procedural assessments and post-procedural management, mitigating complications and enhancing long-term cardiovascular health.

Dr. Mehran’s influence transcends individual clinical trials. She has played an essential role in shaping international cardiovascular practice guidelines through her consistent participation in guideline committees. Her contributions have fostered consensus on managing complex cardiovascular diseases, particularly in tailoring interventions based on risk stratification, which has been a foundational paradigm shift toward precision cardiovascular care.

Leadership is a recurring theme in Dr. Mehran’s career. She holds prominent roles including the vice presidency on the Board of Trustees at the American College of Cardiology (ACC) for 2025-2026 and serves as Chief Scientific Officer of the Cardiovascular Research Foundation (CRF). Through these influential platforms, she champions innovative research agendas and fosters collaborative networks that accelerate scientific discovery and clinical translation globally.

In addition to her robust academic and clinical research endeavors, Dr. Mehran has pioneered programs addressing gender disparities in cardiovascular medicine. She leads the Lancet Commission on Women’s Cardiovascular Diseases, an initiative mobilizing global expertise to elucidate sex-specific differences in cardiovascular physiology, disease progression, and therapeutic responses. This work aims to bridge critical knowledge gaps and promote equitable clinical trial representation.

Further advancing women’s cardiovascular health, Dr. Mehran directs the Women’s Heart and Vascular Center at Mount Sinai Fuster Heart Hospital. This center integrates multidisciplinary approaches catering exclusively to female patients’ unique pathophysiological and psychosocial cardiovascular risk factors. This integration exemplifies the transition toward specialized clinical pathways that acknowledge and address sex-specific cardiovascular manifestations.

Among her many accolades, Dr. Mehran has garnered numerous elite awards that signify her extensive impact on cardiology and medical science. Highlights include the 2016 American College of Cardiology’s Bernadine Healy Leadership Award, the 2019 European Society of Cardiology Silver Medal, the 2024 Icahn School of Medicine’s Jacobi Medallion, and notably, the 2025 ESC Gold Medal. These awards reflect both her scientific excellence and leadership in fostering research innovations.

Mount Sinai Health System, home to Dr. Mehran’s distinguished career, ranks among the world’s preeminent centers for cardiovascular care and research. The Mount Sinai Fuster Heart Hospital is nationally acclaimed, positioning second in the United States for cardiology and heart surgery according to U.S. News & World Report, and is recognized globally by Newsweek among the top specialized hospitals. This institutional excellence synergizes with Dr. Mehran’s work, creating an environment conducive to cutting-edge cardiovascular discoveries.

The recognition by the ESC not only celebrates Dr. Mehran’s individual achievements but also elevates the visibility of interventional cardiology’s evolving landscape. Interventional cardiology has rapidly progressed with advancements in device technology, procedural techniques, and perioperative pharmacotherapy, all areas where Dr. Mehran’s research has been influential. Her work has emphasized the seamless fusion of bench research with bedside applications, ensuring that innovative therapies translate into tangible clinical benefits.

This award highlights the pivotal role of mentorship and collaborative science in cardiovascular medicine. Dr. Mehran consistently emphasizes that such honors reflect the collective efforts of diverse teams, including junior investigators, clinical collaborators, and institutional support systems. Her commitment to nurturing the next generation ensures ongoing progress in a field that demands continuous innovation to combat the global burden of cardiovascular diseases.

The cardiovascular research community worldwide acknowledges that addressing the multifaceted challenges of cardiovascular disease requires dynamic leadership and interdisciplinary collaboration. Dr. Mehran’s career exemplifies this holistic approach, integrating clinical insights, methodical research, and advocacy for inclusivity and equity in medicine. The ESC Gold Medal serves as a beacon of scientific rigor, leadership, and dedication to patient-centered innovation in cardiovascular health.

As cardiovascular diseases remain a leading cause of global morbidity and mortality, the scientific contributions of thought leaders like Dr. Mehran are fundamental to improving outcomes. Her pioneering efforts in stratifying patient risk, refining interventional procedures, and addressing sex-specific disparities represent critical strides toward personalized cardiology and equitable healthcare. The broader impact of her work is undeniable in shaping the future landscape of cardiovascular medicine.

Subject of Research: Cardiovascular medicine, Interventional cardiology, Personalized risk assessment, Women’s cardiovascular health

Article Title: Dr. Roxana Mehran Awarded the European Society of Cardiology Gold Medal for Transformative Contributions to Cardiovascular Medicine

News Publication Date: August 29, 2025

Web References:

• https://mediasvc.eurekalert.org/Api/v1/Multimedia/4f02774c-7860-4824-909b-af93660b348d/Rendition/low-res/Content/Public
• https://www.mountsinai.org/
• https://www.escardio.org/

References: Not provided in original content

Image Credits: Mount Sinai Health System

Keywords: Cardiology, Cardiovascular disorders, Interventional cardiology, Clinical trials, Personalized medicine, Women’s cardiovascular health, Cardiovascular research, ESC Gold Medal

Over the years, TCT® has cemented its reputation as the foremost venue for unveiling data that profoundly influence patient care and therapeutic guidelines in cardiovascular medicine. The symposium’s late-breaking clinical trials sessions remain among the most eagerly anticipated components, offering the first presentation of novel device technologies, pharmaceutical agents, and interventional techniques designed to improve outcomes in heart and vascular disease. In 2025, the program includes 28 such trials that underscore recent innovations targeting minimally invasive procedures, drug delivery systems, and diagnostic technologies.

Among the highlights slated for Sunday, October 26, are the one-year results of the SELUTION DeNovo trial. This randomized study compares percutaneous coronary intervention (PCI) using a sirolimus-eluting balloon combined with provisional stenting against the conventional approach of systematic drug-eluting stent (DES) implantation for de novo coronary lesions. The nuanced understanding of vascular healing and restenosis suppression offered by sirolimus drug delivery could redefine interventional strategies in complex coronary disease.

Another significant focus on this day is the randomized comparison between intravascular lithotripsy and cutting balloon angioplasty for calcified coronary artery disease, as demonstrated in the Short-CUT and VICTORY trials. These studies evaluate the mechanobiological impact and procedural efficacy of lithotripsy—a novel modality employing sonic pressure waves to fracture calcific plaques—contrasted with conventional mechanical plaque modification techniques. The findings could optimize lesion preparation protocols and improve stent expansion in heavily calcified vessels, a notorious challenge in interventional cardiology.

The day’s scientific agenda further includes analyses from the STORM-PE trial on mechanical thrombectomy combined with anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. This multicenter investigation assesses whether adjunctive thrombectomy enhances clot clearance and improves hemodynamic parameters without increasing bleeding risk, an important step toward refining pulmonary embolism management.

Monday, October 27, delves deeply into valvular heart disease and long-term device outcomes. The PREVUE-VALVE study presents critical epidemiological data defining the prevalence of valvular disease among the older American population, drawing attention to the rising clinical burden and the need for optimized screening and management pathways. Complementarily, the seven-year clinical and echocardiographic follow-up of the PARTNER 3 low-risk randomized trial provides invaluable insights into the durability and safety profile of transcatheter aortic valve replacement (TAVR) in a broader demographic.

Technological innovation in mitral valve interventions takes center stage with presentations on the Tendyne Transcatheter Mitral Valve System and the SAPIEN M3 balloon-expandable valve, both examining outcomes in complex mitral annular calcification and transseptal mitral valve replacement, respectively. These studies exemplify the ongoing evolution of structural heart disease therapy toward less invasive, catheter-based solutions with durable, physiological restoration of valve function.

Further enriching the program is the INFINITY-SWEDEHEART randomized trial, which contrasts the Bioadaptor device—a novel bioresorbable scaffold—against contemporary drug-eluting stents in coronary artery disease. In parallel, the OCVC-BIF study interrogates the comparative utility of drug-coated versus conventional balloons for side branch treatment in bifurcation lesions, a niche yet highly relevant clinical scenario prone to restenosis and procedural complexity.

Tuesday, October 28, features pivotal data addressing revascularization strategies in surgical and STEMI populations. The PROCTOR trial offers a landmark comparison of PCI in native coronary arteries versus saphenous vein grafts in post-coronary artery bypass surgery patients, shedding light on procedural success rates, graft patency, and long-term clinical endpoints. The adjunctive use of low-dose intracoronary recombinant tissue plasminogen activator during primary PCI in STEMI patients with large thrombus burdens, assessed in a randomized double-blind trial, could further advance reperfusion strategies and mitigate microvascular obstruction.

The agenda also includes innovative approaches leveraging advanced imaging and physiological assessments to guide revascularization. For instance, the comparison of instantaneous wave-free ratio (iFR) versus cardiac magnetic resonance imaging (MRI) guided strategies for treating non-culprit lesions in ST-elevation myocardial infarction patients represents a cutting-edge attempt to individualize intervention based on functional and tissue characterization markers. Moreover, the PROMISE trial’s stratified treatment approach for myocardial infarction with non-obstructive coronary arteries (MINOCA) addresses an under-recognized patient subset, highlighting the challenge of tailored therapy in heterogeneous pathophysiologies.

Device innovation rigor continues with head-to-head randomized trials such as TUXEDO-2, comparing Supraflex Cruz with Xience drug-eluting stents in diabetic patients with multivessel coronary disease. The 3-year results of the iCABG trial offer new perspectives on the role of angiography and physiology in guiding coronary artery bypass grafting. Additionally, the TALENT multicenter study pits Supraflex CruzTM stents against SYNERGYTM, pushing the frontier in scaffold technology and polymer design.

Complementing the interventional studies, a prospective trial evaluating hemodynamic support devices—novel percutaneous ventricular assist devices (pVADs) versus intra-aortic balloon pumps (IABP)—will provide insightful data on circulatory support strategies for high-risk PCI cases. Meanwhile, the AI-enabled ECG interpretation trial in STEMI patients from a multicenter U.S. registry exemplifies the transformative interface of artificial intelligence with acute cardiovascular care, promising earlier detection and swift therapeutic escalation.

Finally, the INVEST CTO single-arm study explores planned investment procedures in high-risk chronic total occlusions, an area with significant procedural complexity and risk where scaffold scaffolding or lesion preparation strategies may vastly improve success rates.

The upcoming TCT® 2025 promises an unparalleled confluence of scientific breakthroughs and clinical insights, reinforcing its standing as a preeminent forum that equips cardiovascular specialists with the latest evidence to enhance patient survival, quality of life, and procedural safety. Media engagement and open dissemination of these results will expedite their translation from bench to bedside, ultimately shaping the future landscape of cardiovascular therapeutics.

Subject of Research: Late-breaking clinical trials and innovations in interventional cardiovascular medicine presented at TCT® 2025.

Article Title: Revolutionizing Cardiovascular Care: A Preview of Late-Breaking Trials and Innovations at TCT® 2025

News Publication Date: August 27, 2025

Web References:
https://www.tctconference.com/late-breaking-research
https://www.tctconference.com/press-registration
https://x.com/crfheart
http://www.crf.org
http://www.tctconference.com

Keywords: Interventional cardiovascular medicine, percutaneous coronary intervention, drug-eluting stents, intravascular lithotripsy, pulmonary embolism, valvular heart disease, transcatheter mitral valve replacement, bioresorbable scaffolds, coronary artery bypass grafting, STEMI, myocardial infarction, drug-coated balloons, artificial intelligence in cardiology

The Andreas Grüntzig Ethica Award, recognized as the highest accolade within the interventional cardiology community, applauds those who have significantly contributed to the mission of PCR—to enhance patient outcomes by sharing knowledge, experience, and best practices in cardiovascular interventions. The Swedish registries SWEDEHEART and SCAAR stand at the forefront of these efforts, reflecting decades of data collection coupled with clinical insights that have reshaped cardiac care on a global scale.

SWEDEHEART, which emerged officially in 2009 from the consolidation of four national registries initiated in the 1990s, embodies a comprehensive platform that captures detailed data on every hospitalised patient with acute and chronic cardiovascular diseases in Sweden. Its reach encompasses not only the collection of patient demographics and procedural attributes but also emphasizes continuous quality monitoring. By benchmarking care quality across hospitals within the country, SWEDEHEART has fostered an environment of transparency and ongoing quality improvement that directly benefits patients.

The interventional component, SCAAR, specifically focuses on coronary angiography and percutaneous coronary interventions. Its meticulous data capture spans every procedure undertaken, every patient treated, and every outcome recorded longitudinally. This granular, near-real-time data accumulation has enabled clinicians and researchers to identify trends, evaluate safety and efficacy, and refine clinical protocols to optimize patient care—a rare accomplishment in cardiovascular registries worldwide.

One of SWEDEHEART’s most revolutionary contributions lies in its facilitation of registry-based randomized clinical trials (R-RCTs). This novel hybrid trial design leverages existing registry infrastructure to enrol and follow large patient populations within routine clinical practice, dramatically reducing the time and cost associated with traditional randomized controlled trials. Such pragmatic trials maintain scientific rigor while enhancing generalizability, a methodological evolution that has since been adopted globally, spurring numerous impactful studies.

The extensive dataset housed within SWEDEHEART has spurred over 500 high-impact scientific publications, advancing the understanding of cardiovascular diseases and their management. From dissecting the nuances of acute myocardial infarction interventions to evaluating long-term outcomes of various treatment modalities, these insights have ushered in evidence-based changes in clinical guidelines and practice not only in Sweden but across international borders.

Professor William Wijns, Chair of the PCR Board, underscored the visionary nature of these registries, highlighting their inception long before ‘big data’ became a medical buzzword. The continuous capture and analysis of procedural data linked with clinical outcomes in such an exhaustive manner set new standards for cardiovascular research and quality assurance. These insights have bridged knowledge gaps, informing therapeutic decision-making with unparalleled precision.

Beyond research and quality monitoring, SWEDEHEART exemplifies a crucial bulwark against healthcare disparities. By openly reporting performance metrics, the registry fosters accountability and equity, ensuring that patients across diverse regions receive consistent and effective cardiac care. This systemic transparency has catalyzed improvements in healthcare delivery, reflecting a model for other nations striving toward equitable health systems.

The success of SWEDEHEART has inspired analogous initiatives globally, with national and international registries adopting similar frameworks to harness real-world data for cardiovascular research. This global ripple effect speaks to the foundational work spearheaded by the Swedish teams, whose dedication created a replicable paradigm for integrating data science and clinical practice.

At the upcoming EuroPCR 2025 course, the celebration of this achievement aligns with PCR’s mission to empower the cardiovascular community through education and knowledge exchange. The event, held from 20 to 23 May in Paris, will spotlight innovations such as SWEDEHEART, fostering dialogues on data-driven medicine and its transformative potential in patient care worldwide.

The recognition of Professors Wallentin, James, and their colleagues illustrates the critical role of clinical registries as a nexus between large-scale data collection, rigorous scientific analysis, and real-world clinical application. Their work embodies a synthesis of epidemiology, biostatistics, and interventional cardiology, offering a blueprint for future endeavors aspiring to elevate cardiovascular health outcomes.

As cardiovascular diseases remain a leading cause of morbidity and mortality globally, the insights garnered from SWEDEHEART and SCAAR epitomize how systematic data collection and collaborative research can fuel innovations that save lives. This parsimonious approach leveraging existing clinical workflows minimizes burden while maximizing data utility, a testament to strategic registry design and clinical engagement.

The Andreas Grüntzig Ethica Award thus shines a spotlight not only on individual achievements but also on the collaborative ecosystem propelling cardiovascular medicine into a new era defined by data integration and continuous quality enhancement. It reflects an inspiring narrative where cutting-edge technology and clinical dedication converge to reshape the future of interventional cardiology.

In celebrating this milestone, the global cardiovascular community affirms the indispensable value of registries as instruments for scientific discovery, clinical excellence, and ultimately, patient benefit. As SWEDEHEART continues to evolve, it will undoubtedly remain a beacon of innovation, fostering further advancements and setting standards for how big data can revolutionize cardiovascular care across borders.

Subject of Research: Cardiovascular disease registries and their impact on interventional cardiology and patient care enhancement.

Article Title: Swedish Cardiovascular Registries SWEDEHEART and SCAAR Honored with Andreas Grüntzig Ethica Award for Revolutionizing Interventional Cardiology

News Publication Date: 20 May 2025

Web References:

• EuroPCR Programme: https://www.pcronline.com/Courses/EuroPCR/Programme%C2%A0
• PCR Official Website: http://www.pcronline.com

Keywords: Cardiology, Interventional Cardiology, Cardiovascular Registries, SWEDEHEART, SCAAR, Percutaneous Coronary Intervention, Registry-Based Randomized Trials, Cardiovascular Research, Quality Improvement, Big Data in Medicine

As global statistics reveal a staggering 60% increase in cardiovascular disease-related deaths over the past three decades, the urgency for innovative solutions has never been more critical. The rising death toll accentuates the vital need for advanced technologies and therapeutic strategies within the field of cardiovascular health. Attendees at the SCAI 2025 Scientific Sessions witnessed firsthand the promising data on emerging treatment devices, offering hope for individuals at significant risk of serious cardiovascular complications. SCAI President James B. Hermiller, MD, emphasized the crucial investment in innovation to meet the growing demands posed by the increasing prevalence of cardiovascular diseases.

One of the focal points of discussion was the percutaneous ventricular assist device (pVAD), designed specifically for patients requiring severe cardiovascular interventions. This device serves a pivotal role in enhancing blood flow during high-risk percutaneous coronary interventions (HRPCI). These patients often present with advanced coronary artery disease and other complex comorbidities, making them susceptible to serious complications. The small access Supira System pVAD offers temporary, but effective, hemodynamic support, achieving a flow rate of 5.5 liters per minute—a critical parameter for patient recovery. A multicenter feasibility study conducted across four sites in the U.S. highlighted the device’s capability to maintain hemodynamic support effectively, with only one major adverse event noted during the procedures.

Results from the clinical study showcased that the pVAD system was not only safe but also effective in patients who are particularly vulnerable following HRPCI. The study enrolled 15 participants with a mean age of 72, revealing a successful procedure completion rate and a low incidence of adverse effects. Dr. David Kandzari, the lead author of the study, remarked on the necessity for continued exploration into the potential applications of pVAD systems beyond HRPCI, suggesting that the technology could be beneficial for patients suffering from cardiogenic shock and advanced heart failure, where circulatory assistance is imperative for better outcomes.

In addition to pVAD systems, the advancements in thrombectomy techniques also made headlines during the conference. Pulmonary embolism, a life-threatening condition that stems from blood clots, presents an urgent clinical challenge with high morbidity and mortality rates. The introduction of the AVENTUS thrombectomy system demonstrates significant progress in this area, as it combines mechanical thrombectomy with inline blood filtration and reinfusion, aiming to deliver efficient clot removal while minimizing blood loss.

A comprehensive pivotal study assessed the AVENTUS device’s safety and effectiveness in treating acute intermediate-risk PE patients. The results were striking, demonstrating a considerable reduction in right ventricular to left ventricular (RV/LV) ratios within 48 hours post-procedure—indicating improved heart function. In addition, the study achieved a compelling measure of safety with no device-related major adverse events reported within the 30-day period following surgeries. Notably, a meaningful increase in functional outcomes was documented through enhanced performance on a six-minute walk test, showcasing significant quality-of-life improvements in the patient cohort.

Dr. Jun Li, lead author of the study, emphasized the device’s potential impact on broader clinical practices, especially in community hospitals where access to advanced therapies may be limited. The device’s intuitive design allows for efficient use, even among less experienced practitioners, highlighting its role in improving healthcare accessibility for underserved populations.

The conference proceedings also shed light on carotid artery stenosis, a condition that elevates stroke risks and often necessitates intervention. The PERFORMANCE II trial investigated the Neuroguard IEP® 3-in-1 Carotid Stent System’s efficacy, designed to treat high-risk patients suffering from CAS. Results from the study underscored the stent system’s safety and durability with an impressive low event rate concerning major adverse events during the 30-day follow-up period. The study encapsulated not only immediate procedural safety but also long-term outcomes, reporting no major strokes or neurological deaths within the evaluated timeframe.

A total of 305 patients participated in the PERFORMANCE II trial across 32 sites in the U.S. and Europe, marking a significant commitment to ensuring effective care for individuals at heightened risk. The findings from this innovative approach advocate for carotid stenting as a reliable treatment option that offers favorable outcomes, establishing an effective strategy for managing obstructive carotid artery disease in high-risk populations.

As the SCAI 2025 Scientific Sessions concluded, there was a palpable sense of optimism in the air about the future of cardiovascular healthcare. Each of these device innovations points towards a profound transformation in not only how cardiovascular diseases are approached but also how patient care is revolutionized. The studies presented are not merely academic but carry substantial implications for clinical practices, advocating for broader access to advanced therapies, especially in communities that face significant health disparities.

The commitment to research and the dissemination of knowledge among healthcare professionals is paramount in combating the ever-increasing threat posed by cardiovascular disease. Both current and future innovations hinge on collaborative efforts to identify and fulfill the unmet needs of patients, guiding the trajectory of treatment advancements for conditions that pose significant challenges globally. The SCAI 2025 Scientific Sessions embodied this spirit of innovation, uniting thought leaders in interventional cardiology and setting the stage for groundbreaking developments to come.

The emphasis on continued clinical trials going forward reflects a robust dedication to ascertain the long-term efficacy of these devices. The evidence gathered from studies such as those on the pVAD system, AVENTUS thrombectomy system, and Neuroguard IEP® carotid stent system will undoubtedly lead to enhancements in patient outcomes and increased survival rates for vulnerable populations. As we witness the evolution of interventional cardiology, it is imperative that the medical community remains steadfast in its pursuit of excellence, ensuring that cutting-edge technologies translate into tangible benefits for patients worldwide.

Through these shared insights from the SCAI 2025 Scientific Sessions, it is clear that innovation will remain at the forefront of tackling cardiovascular diseases, ultimately leading to safer and more effective treatments across a spectrum of patient needs. The collective ambition to inspire and implement change reaffirms the necessity for ongoing collaboration within the cardiovascular community, shaping the future of heart health for generations to come.

Subject of Research: Cardiovascular Innovations at SCAI 2025
Article Title: Innovative Cardiovascular Technologies Unveiled at SCAI Scientific Sessions 2025
News Publication Date: May 1, 2025
Web References: SCAI Official Website, AVENTUS Thrombectomy Study
References: Performance II Study, pVAD System Research Publications
Image Credits: Society for Cardiovascular Angiography & Interventions

Keywords

Cardiovascular disease, Pulmonary embolism, Carotid artery stenosis, pVAD system, Thrombectomy, Neuroguard stent system, Interventional cardiology, Cardiac support technologies, Clinical innovations, Patient outcomes

Acute coronary syndrome, a spectrum of conditions marked by sudden reduced blood flow to the heart, remains a formidable cause of morbidity and mortality globally. Coronary angiography, an imaging technique that visualizes coronary arteries, combined with PCI, a minimally invasive procedure to open blocked arteries, represents the cornerstone of contemporary ACS treatment. However, disparities in access to these interventions persist, especially in low- and middle-income countries, thus raising pressing questions about the equity and efficiency of cardiovascular care delivery. The study in question harnesses a robust propensity-matched cohort design, enabling a meticulous comparison between patients who received these procedures and those who did not, controlling for confounding variables to elucidate the true effect of these interventions on survival.

One of the most compelling findings from this Malaysian cohort is the significant reduction in both in-hospital and five-year mortality for patients who underwent coronary angiography followed by PCI. The data suggest that the availability of such interventional approaches fundamentally transforms patient trajectories, converting what could be fatal cardiac episodes into manageable acute events with promising prognoses. The researchers’ employment of propensity score matching meticulously balanced baseline characteristics, thus lending credibility to the observed survival advantage directly attributable to the access and application of these technologies.

Delving into the technical underpinnings, coronary angiography employs catheter-based imaging to delineate coronary vessel anatomy and pinpoint areas of stenosis or occlusion. This real-time visualization permits precise therapeutic targeting, a remarkable advance over previous eras where treatment decisions relied on indirect assessments and less sensitive diagnostic tools. PCI, typically involving balloon angioplasty and stent implantation, physically reopens constricted arteries, restoring perfusion to ischemic myocardium. This mechanical restoration of blood flow curtails tissue necrosis, mitigates the extent of myocardial infarction, and thereby improves clinical outcomes both acutely and in the long term.

The context of Thailand presents an intriguing backdrop in this study, reflective of a healthcare system progressively integrating advanced cardiac care modalities amid resource limitations. The researchers shed light on how strategic allocation of interventional cardiology resources in tertiary centers impacts survival rates. Importantly, the study underscores that it is not merely the availability of PCI technology but effective patient triage and timely intervention that define survival odds. Time-to-treatment remains a critical metric; delayed angiography or PCI correlates with progressively diminishing returns on survival, emphasizing the need for optimized care pathways.

Moreover, the findings reveal the nuanced role that socioeconomic, geographic, and institutional factors play in determining access. Patients residing in urban centers with proximity to specialized cardiac hospitals had markedly higher rates of receiving coronary angiographies and subsequent PCI compared to those in rural locales. This urban-rural divide in treatment accessibility calls for targeted health policy reforms aimed at decentralizing cardiovascular services or enhancing rapid transport mechanisms for critically ill patients, thereby bridging care disparities.

Beyond immediate mortality benefits, the study also highlights the profound impact of PCI on five-year survival, a testament to the procedure’s capacity to alter disease progression fundamentally. Long-term outcomes are influenced not only by restored coronary patency but also by ancillary factors such as optimized medical therapy, adherence to secondary prevention strategies, and comprehensive cardiac rehabilitation—all elements integral to the post-PCI care continuum. The study’s long follow-up duration offers robust evidence supporting sustained benefits from early invasive strategies in ACS management.

Intriguingly, this research addresses concerns about overuse or potentially unnecessary procedures by demonstrating that in properly selected patients, these interventions exert a substantial net benefit without exposing individuals to undue procedural risks. This balanced perspective is vital in crafting clinical guidelines that advocate for invasive management tailored to patient risk profiles, rather than blanket approaches or overly conservative treatment.

The methodological rigor of this study is noteworthy. By harnessing advanced statistical techniques such as propensity matching, the researchers have minimized bias inherent in observational data, thus approaching the causal inference strength often reserved for randomized controlled trials. This analytical approach enhances the reliability of conclusions, setting a benchmark for future health outcomes research in similar clinical contexts.

Ethical considerations underpinning this study are also integral, as the equitable allocation of life-saving interventions raises challenging questions about healthcare priorities. The authors tacitly prompt stakeholders to consider not only clinical efficacy but also ethical distribution, advocating for policies that expand access without compromising care quality or diverting resources disproportionately. Such discussions resonate globally as health systems confront escalating demands amid constrained budgets.

In the broader narrative of cardiovascular medicine, this study contributes importantly to a growing body of evidence affirming the transformative impact of early invasive strategies. It challenges clinicians and policymakers alike to reimagine ACS management paradigms, integrating technological advances within pragmatic models that prioritize timely access. The compelling survival data confer urgency to ongoing efforts to bolster infrastructure, train interventionalists, and refine protocols ensuring that PCI and angiography are not privileges but standard care components accessible to all patients at risk.

Furthermore, the study’s findings dovetail with emerging research emphasizing multidisciplinary collaboration. Effective management of ACS extends beyond the catheter lab; it requires coordinated efforts among emergency medical services, cardiologists, nursing staff, and rehabilitation specialists. Thailand’s example serves as a microcosm illustrating how integrated care pathways can amplify survival benefits in resource-variable settings.

Technological innovation continues to revolutionize PCI and angiography, with advances such as drug-eluting stents, fractional flow reserve measurements, and intravascular imaging offering even greater precision and efficacy. The study’s results reinforce the imperative that such cutting-edge technologies be disseminated equitably, ensuring that patient survival is no longer dictated by geographic or economic disparities but by evidence-based standards of care universally applied.

In conclusion, this landmark study compellingly delineates the life-saving potential of coronary angiography and percutaneous coronary intervention in ACS patients within Thailand’s healthcare landscape. By demonstrating significant reductions in immediate and long-term mortality, it offers a clarion call for healthcare systems globally to prioritize access to these essential interventions. The findings illuminate pathways to optimize cardiovascular care delivery, enhance patient outcomes, and ultimately, save lives on a broad scale. As cardiovascular disease remains the leading cause of death worldwide, such research provides hope and strategic direction for overcoming persistent challenges in the fight against heart disease.

Subject of Research: Impact of access to coronary angiography and percutaneous coronary intervention on mortality outcomes in acute coronary syndrome patients

Article Title: Impact of access to coronary angiography and percutaneous coronary intervention on in-hospital and five-year mortality in patients with acute coronary syndrome: a propensity-matched cohort study in Thailand

Article References:
Kumwichar, P., Thungthong, J., Liabsuetrakul, T. et al. Impact of access to coronary angiography and percutaneous coronary intervention on in-hospital and five-year mortality in patients with acute coronary syndrome: a propensity-matched cohort study in Thailand. Glob Health Res Policy 9, 48 (2024). https://doi.org/10.1186/s41256-024-00390-x

Image Credits: AI Generated

Dr. Windecker’s contributions to interventional cardiology have significantly shifted paradigms and established new benchmarks of excellence within the community. Holding prominent roles, including Chairman of the Department of Cardiology at the Cardiovascular Center in Bern, Switzerland, and Professor of Medicine at the University of Bern, Dr. Windecker has cultivated a reputation as a transformative figure in cardiovascular care. His focus on transcatheter heart valve interventions has propelled the field forward, leading to better patient outcomes and evolving standards of care.

The TCT® Career Achievement Award recognizes individuals whose work has notably elevated the practice and science of interventional cardiology. Dr. Windecker’s extensive research and clinical impact exemplify the award’s criteria, having authored over 1,000 peer-reviewed publications and contributed significantly to over 100 review articles. His dedication to the advancement of clinical practices and the training of future healthcare leaders illustrates a commitment that resonates deeply within the cardiovascular community. The recognition of his work through prestigious awards not only honors his past achievements but also inspires ongoing innovations in the field.

Martin B. Leon, MD, a foundational figure in CRF® and a program director for TCT® 2025, emphasizes the importance of mentors like Dr. Windecker in shaping the future of medicine. In reflecting on Dr. Windecker’s impact, he noted that his pioneering contributions have reshaped clinical practices globally. The acknowledgement of his work is not simply a retrospective honor, but rather it signifies a continuous influence on fellow researchers and physicians in the field. The drive to advance cardiovascular medicine stems from a collaborative spirit, one that Dr. Windecker embodies through his engagement with peers and mentees alike.

Dr. Windecker’s groundbreaking research extends to the evaluation of intracoronary devices and antithrombotic therapies for patients undergoing cardiac device implantation. His rigorous investigation into minimally invasive transcatheter interventions for valve diseases has made remarkable strides in enhancing procedural safety and efficacy. As the field of cardiology continues to evolve, Dr. Windecker’s efforts have ensured that best practices are established and disseminated among practitioners, thereby benefiting multidisciplinary teams across the globe.

The recognition of Dr. Windecker comes as a culmination of his unwavering commitment and passion for improving patient care. In accepting the award, Dr. Windecker articulated the essence of collaboration in medicine, expressing gratitude toward the mentors and colleagues who shaped his journey. This acknowledgment reinforces the notion that the road to progress in healthcare is paved with collective endeavors, underscoring the interconnectedness of efforts within the medical community.

Moreover, the European Society of Cardiology (ESC) has benefitted from Dr. Windecker’s leadership, as he currently holds the position of Secretary and Treasurer. His involvement in various committees has been instrumental in driving forward initiatives that prioritize innovation and efficacy in cardiovascular medicine. His leadership within the ESC demonstrates a long-standing commitment to nurturing a community that emphasizes gender equity and strategic advancements in device innovation.

The celebration of Dr. Windecker’s achievements serves as a source of inspiration for the next generation of practitioners. Roxana Mehran, MD, TCT® 2025 Program Director, encapsulates this sentiment by acknowledging Dr. Windecker as a "prince" of interventional cardiology, someone who has set a high standard for excellence. His ability to mentor aspiring cardiologists while simultaneously pushing the boundaries of scientific inquiry represents a dual commitment to education and innovation in the field.

Juan F. Granada, MD, another program director for TCT® 2025, sums up the significance of Dr. Windecker’s accolade by stressing that honoring such a leader is crucial in promoting the standards of excellence that define the field of interventional cardiology. Under Dr. Windecker’s continuous guidance, forthcoming generations are likely to explore new frontiers in cardiovascular treatments, ultimately improving care protocols and patient experiences. His embodiment of humanistic principles alongside a rigorous academic ethos creates a role model worth emulating in future cardiovascular advancements.

Outside academic settings, Dr. Windecker’s recognition transcends individual accomplishments. His membership in esteemed institutions and receipt of distinguished awards highlight the inherent value of collaboration. Being a Fulbright Scholar and receiving accolades from the American College of Cardiology underscores his significant role not only within the context of interventional cardiology but also in global health dialogues. This breadth of impact showcases that effective healthcare leaders must not only achieve personal success but actively contribute to the vitality of the wider medical tapestry.

In light of the impending award ceremony, upcoming symposium participants prepare for an enriching experience wherein they will engage with groundbreaking research, attend expert-led presentations, and exchange ideas with peers. TCT® continues to serve as an incubator for new thoughts, integrating years of clinical expertise with innovative technological advancements within the cardiovascular field. The confluence of academic rigor, practical implementation, and the nurturing of conscious collaboration exemplifies the spirit of TCT®.

The legacy of innovation that Dr. Windecker contributes to serves as a beacon of hope for many living with cardiovascular disease. With his research leading the charge towards personalized interventions and patient-centric approaches, the future of cardiology appears promising. His work serves as a reminder of the power of individual excellence powered by collaboration, leading to exceptional outcomes that transform lives. As the cardiology community prepares to celebrate Dr. Windecker’s career achievements, it is certain that the impact of his work will continue to be felt for years to come in the realm of interventional cardiovascular medicine.

As we approach TCT® 2025, the anticipation surrounding both the award presentation and the rich agenda of the conference reflects a mutual commitment to advancing knowledge, sharing experiences, and further enhancing the quality of care delivered to patients. Together, under the banner of collaboration and excellence, the cardiovascular medicine community looks forward to celebrating extraordinary achievements, such as those of Dr. Windecker, while always aspiring for more innovative breakthroughs.

Subject of Research: Interventional Cardiology

Article Title: Stephan Windecker, MD, to Receive TCT® 2025 Career Achievement Award

News Publication Date: April 11, 2025

Web References: www.crf.org, www.tctconference.com

References: Cardiovascular Research Foundation publications, TCT® archives

Image Credits: CRF®

Keywords: Interventional cardiology, TCT® 2025, Cardiovascular Research Foundation, Stephan Windecker, transcatheter heart valve interventions, medical innovation, mentoring in medicine